[1]牙韩达,韦亚娜,吴 燕.克唑替尼治疗非小细胞肺癌的研究[J].医学信息,2019,32(21):43-45.[doi:10.3969/j.issn.1006-1959.2019.21.015]
　YA Han-da,WEI Ya-na,WU Yan.Crizotinib in the Treatment of Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):43-45.[doi:10.3969/j.issn.1006-1959.2019.21.015]
点击复制

克唑替尼治疗非小细胞肺癌的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年21期
页码:
43-45
栏目:
综述
出版日期:
2019-11-01

文章信息/Info

Title:
Crizotinib in the Treatment of Non-small Cell Lung Cancer
文章编号:
1006-1959（2019）21-0043-03
作者:
牙韩达; 韦亚娜; 吴 燕
（广西河池市人民医院肿瘤科，广西 河池 547000）
Author(s):
YA Han-da; WEI Ya-na; WU Yan
(Department of Oncology,Hechi People's Hospital,Hechi 547000,Guangxi,China)
关键词:
非小细胞肺癌; 克唑替尼; 作用机制; 药代动力学; 药理毒理
Keywords:
Non-small cell lung cancer; Crizotinib; Mechanism of action; Pharmacokinetics;  Pharmacology and toxicology
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.21.015
文献标志码:
A
摘要:
非小细胞肺癌（NSCLC）是肺癌常见类型，早期诊断难度较大，5年生存率低。克唑替尼作为抑制Met/ALK/ROS的ATP竞争性的多靶点蛋白激酶抑制剂，是治疗NSCLC的分子靶向药物，在控制变性淋巴瘤激酶（ALK）阳性NSCLC患者疾病发展中具有重要意义，可有效延长患者无进展生存期，且较化疗毒副反应更小，患者耐受性高，但克唑替尼的耐药性也是临床关注重点。本文主要对克唑替尼治疗NSCLC、克唑替尼药理作用及其临床效果、耐药后治疗等进行综述，旨在为更好的发挥该药治疗效果，为临床治疗NSCLC提供参考依据。
Abstract:
Non-small cell lung cancer (NSCLC) is a common type of lung cancer. It is difficult to diagnose early and has a 5-year survival rate. Crizotinib, a multi-target protein kinase inhibitor that inhibits ATP competition in Met/ALK/ROS, is a molecularly targeted drug for the treatment of NSCLC and is important in controlling disease progression in patients with degenerative lymphoma kinase (ALK)-positive NSCLC. Significance can effectively prolong the progression-free survival of patients, and is less toxic than chemotherapy, and patients are highly tolerant, but the resistance of crizotinib is also the focus of clinical attention. This article is mainly to review the pharmacological effects of crizotinib in the treatment of NSCLC, crizotinib and its clinical effects, treatment after drug resistance, etc., in order to better play the therapeutic effect of this drug, and provide a reference for clinical treatment of NSCLC.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]石远凯,孙燕,于金明,等.中国肺癌脑转移诊治专家共识(2017年版)[J].中国肺癌杂志,2017,20(1):1-13. [3]陈瑞琳,张程程,张永庆,等.克唑替尼靶向治疗非小细胞肺癌疗效及EML4-ALK的表达情况分析[J].临床肺科杂志,2018,23(1):149-152. [4]郭伟,张霞,许君君,等.克唑替尼治疗间变性淋巴瘤激酶重排晚期非小细胞肺癌疗效观察[J].山西医药杂志,2018,47(13):1579-1580. [5]李亚平,赵蓉.克唑替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的疗效及不良反应的影响因素[J].癌症进展,2019,17(8):922-924,928. [6]焦婷,李京云.梁月勉.克唑替尼对ALK阳性NSCLC患者CNS的影响[J].中国现代医学杂志,2018,23(2):83-86. [7]高海祥,邢荣芹,许金伟,等.AKT信号通路在克唑替尼诱导的EML4-ALK阳性肺癌细胞凋亡迁移中的作用及机制研究[J].癌症进展,2017,15(2):132-135. [8]宋玲玲,刘红梅,黄媚娟,等.克唑替尼治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌患者的临床疗效分析[J].华西医学,2016,31(1):43-47. [9]杭猛,陈暑波,孙清,等.GP方案联合康莱特注射液治疗晚期非小细胞肺癌的疗效及安全性分析[J].实用癌症杂志,2017,32(2):289-291. [10]蒋小雯,张俊华,王文娴,等.克唑替尼治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌患者的疗效与安全性分析[J].中华全科医师杂志,2016,15(12):936-940. [11]朱广迎,于会明,郑明英.克唑替尼与化疗在ALK阳性晚期非小细胞肺癌颅内疾病控制率的比较[J].循证医学,2016,16(4):218-221. [12]丁永英,朱秀华,程先鸣.克唑替尼治疗进展期ALK阳性非小细胞肺癌的临床疗效研究[J].实用癌症杂志,2016,31(3):474-476. [13]陈文武,毛良平,牟方红,等.克唑替尼靶向治疗的非小细胞肺癌患者血清肿瘤标志物水平变化及意义[J].山东医药,2017,57(29):62-64. [14]姚舒洋,张毅,胡牧,等.克唑替尼与含铂两药方案治疗棘皮动物微管结合蛋白4-间变性淋巴瘤激酶融合基因阳性晚期非小细胞肺癌疗效与安全性比较[J].药物不良反应杂志,2016,18(2):111-115. [15]高峨嵋,赵军,卓明磊,等.克唑替尼治疗晚期NSCLC患者单中心回顾性分析[J].中国肺癌杂志,2016,19(3):161-168. [16]梁红格,徐燕,钟巍,等.克唑替尼在ALK阳性晚期NSCLC患者中的疗效和安全性评价及其预后影响因素[J].国际肿瘤学杂志,2017,44(5):336-341. [17]毕国放,梁宇光,曲恒燕.克唑替尼在非小细胞肺癌治疗中耐药问题的研究状况[J].中国临床药理学杂志,2016,32(10):952-955. [18]刘潇衍,梁红格,王孟昭.非小细胞肺癌ALK抑制剂耐药后处理策略[J].中华肿瘤防治杂志,2018,25(4):298-302. [19]刘燕，赵凌云.克唑替尼联合沙利度胺治疗老年晚期非小细胞肺癌临床研究[J].临床肺科杂志,2018,23(4):595-597. [20]董莉,张保平,冯新平,等.血浆HSP90α检测在肺癌诊断中的临床应用价值研究[J].现代检验医学杂志,2014,32(4):97-100. [21]江倩,金蒙蒙,黄锐,等.肺癌患者血浆热休克蛋白90α的表达及意义[J].实用医学杂志,2016,32(13):2129-2132. [22]朱礼阳,于忠和.克唑替尼治疗肺癌的疗效及其耐药后的治疗[J].国际肿瘤学杂志,2016,43(7):532-534. [23]梁斐,张晓斐,蔡修宇.既往未行ALK抑制剂治疗的ALK阳性NSCLC应用布加替尼对比克唑替尼的Ⅲ期随机对照研究[J].中国癌症杂志,2019,29(2):78-85. [24]周彩存,黎文锋.艾乐替尼一线治疗ALK阳性晚期非小细胞肺癌显著优于克唑替尼[J].循证医学,2018,18(1):29-32. [25]Gainor JF,Tan DSW,Pas TD,et al.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib[J].Clinical Cancer Research,2016,21(12):2745-2752. [26]Muller IB,Langen AJD,Honeywell RJ,et al.Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib[J].Expert Rev Anticancer Ther,2016,16(2):147-157. [27]Jassem J.Alectinib in crizotinib-resistant，ALK-positive NSCLC[J].Lancet Oncology,2016,17(2):134-135. [28]吴标,庄武,黄诚,等.ALK融合基因阳性晚期肺腺癌克唑替尼耐药后治疗的效果分析[J].临床肿瘤学杂志,2018,23(8):49-53. [29]高海祥.克唑替尼耐药细胞H2228/CR对紫杉醇及顺铂的敏感性变化及机制[J].山东医药,2017,57(4):31-34. [30]高仑,孙秀娥.克唑替尼联合紫杉醇和顺铂治疗ALK阳性非小细胞肺癌的疗效观察[J].现代药物与临床,2016,31(12):1994-1998.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(21):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(21):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(21):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(21):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 2019-11-01